Additionally, stimulation of the B-cell receptor (BCR) signaling activates JAK2 and STAT3, and JAK1/2 inhibitor ruxolitinib induces apoptosis of CLL cells30. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.